BioNxt Announces Promising Results in Cladribine Study

BioNxt Solutions Inc. has reported successful results from its in-vivo dosing study of cladribine. The study compared BioNxt's sublingual orally dissolving film (ODF) to a reference tablet formulation in a pig model, assessing the bioavailability of cladribine, a drug used in treating Multiple Sclerosis (MS).

The results indicate that BioNxt's cladribine ODF exhibits superior bioavailability compared to the tablet form. This suggests efficient drug absorption, potentially improving patient experience by reducing systemic drug exposure and associated side effects. The company is currently analyzing the data internally to complete its findings.

The study's positive outcomes align with BioNxt's strategy to enhance drug delivery and address the growing MS market, which is projected to surpass USD 41 billion by 2033. BioNxt also highlights its strengthened patent portfolio, supporting future commercial and licensing activities.